2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1275

Spectrum of Organ Involvement in Idiopathic Inflammatory Myopathies, Frequency of Comorbidities, and Relationship to Anti-SSA/SSB Positivity
Abstract Number: 576

Spinal Bone Formation as Assessed by Low-Dose CT Scan in Patients with Radiographic Axial Spondyloarthritis – Comparison of the Progression Observed in Vertebrae and Facet Joints
Abstract Number: 969

ß-adrenergic Receptor Activation: A Way to Enhance CD4 T Cell Suppression by Improving Regulatory B Cell Function
Abstract Number: 2192

Stabilization of Patellar Bone-Shape Correlates Significantly with Reduced Knee Pain Frequency After IA TPX-100 in Subjects with Bilateral Patellofemoral OA
Abstract Number: 2165

Stakeholder Feedback on Novel Behavioral Intervention Targeting Comorbid Chronic Back Pain and Depression in Older Adults
Abstract Number: 2030

Staphylococcus Aureus Colonization Is Increased on Lupus Skin Lesions and Is Promoted by Interferon-Mediated Barrier Disruption
Abstract Number: 2453

Static and Longitudinal Construct Validity of PROMIS CAT and Profile29 for Assessing Pain Interference, Physical Function and Fatigue in Psoriatic Arthritis
Abstract Number: 1893

Statin Exposure Moderates the Effects of Chronic Inflammation on Coronary Atherosclerosis Progression and Cardiovascular Events in Rheumatoid Arthritis
Abstract Number: 173

Statin Use Is Associated with Increased Risk of RA in US Population: Results from a Large Nationwide Study
Abstract Number: 998

Stimulation of Splenic Neurovascular Bundle Protect Mice from Developing Collagen-induced Arthritis
Abstract Number: 804

STING-associated Vasculopathy with Onset in Infancy (SAVI Syndrome) Can Mimic Juvenile Idiopathic Arthritis
Abstract Number: 2759

Stopping NSAIDs for Arthritis Pain (SNAP): A Randomized Withdrawal Trial Comparing NSAIDs to Cognitive Behavioral Therapy
Abstract Number: 2236

Strength Training for People with Rheumatoid Arthritis: Barriers, Facilitators, and Tailoring Considerations
Abstract Number: 1603

Stroke Clusters in SLE by Lupus Autoantibodies
Abstract Number: 997

Stromal Cell-derived DCSTAMP Coordinates Cell Migration and Osteoclast Activation in TNF-driven Murine Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].